[Ip-health] Open letter to Gilead: Global civil society calls for no patents or exclusivities on potential COVID-19 treatment
Shailly.GUPTA at geneva.msf.org
Fri Apr 3 03:14:32 PDT 2020
More than 150 organizations and individuals from global health movement sent an open letter<https://msfaccess.org/open-letter-civil-society-urges-gilead-take-immediate-action-ensure-access-potential-covid-19> this week to Gilead’s CEO sharing concerns about Gilead’s current approach to remdesivir, which may obscure access to this potentially critical treatment for COVID-19.
Gilead holds primary patents of remdesivir in more than 70 countries that may block generic entry until 2031. In the letter, Gilead was urged to take immediate actions to:
- Declare that Gilead will not enforce and claim exclusive rights on patents and regulatory and trial data, or any other types of exclusivity anywhere in the world;
- Make publicly available all data, sample products, and know-how that are needed for generic development and for regulatory processes, to facilitate the production and supply by generic manufacturers worldwide; and
- Improve transparency by disclosing its manufacturing capacity and existing supply and allow independent and proper governance over the allocation of the treatment according to medical needs.
MSF Access Campaign
+41- 79 203 13 02
More information about the Ip-health